Stock listing
Frankfurt:BIX0 BioInvent International AB Aktie
German listing (Frankfurt) of BioInvent International AB · home listing Stockholm:BINV
Follow BioInvent International AB into a list and get an email when it puts out news.
Share price · FWB:BIX0
€1.80 EUR +0.02 (+1.4%)
Close on Oct 27, 2026
- Day range
- €1.80 – €1.80 EUROct 27, 2026
- Market cap
- €118.3M EURAt the close on Oct 27, 2026 · price × 65.80M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:BINV · Home | 4.30 SEK | -1.13 (-20.8%) | 2,560,503 | 5.10 | 5.10 | 4.10 | 5.43 | Close on Nov 2, 2026 |
| Frankfurt:BIX0 | €1.798 EUR | +0.024 (+1.4%) | — | €1.798 | €1.798 | €1.798 | €1.774 | Close on Oct 27, 2026 |
- Ticker
- Frankfurt:BIX0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 28, 2026
BioInvent International resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026
Latest earnings call · Feb 26, 2026
Bioinvent International (Stockholm:BINV) Q4 2025 Earnings Call
Replay and transcript
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 49 slides
Calls
Replays
Bioinvent International (Stockholm:BINV) Q4 2025 Earnings Call
Thu, Feb 26, 2026 · 8:00 AM ET
Watch TranscriptBioinvent International (Stockholm:BINV) Q3 2025 Earnings Call
Wed, Oct 29, 2025 · 9:00 AM ET
Watch Transcript
Latest news
Financings
Rights offering of new shares with preferential rights
Oct 28, 2026 · US$43.28M
Announced: about SEK 430M · DNB Carnegie Investment Bank AB (publ)
Dealers: DNB Carnegie Investment Bank AB (publ) (lead)
Buyers: Redmile (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Van Herk (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Forbion (Subscription commitment; together with other existing shareholders approximately SEK 80 million); HealthInvest (Subscription commitment; together with other existing shareholders approximately SEK 80 million); DNB Bank ASA (Guarantee undertakings, with others, up to approximately SEK 270 million); Schonfeld Global Master Fund L.P. (Guarantee undertakings, with others, up to approximately SEK 270 million); Anavio Capital Partners LLP (Guarantee undertakings, with others, up to approximately SEK 270 million)
Insiders: Shareholding board members and management intend to subscribe approximately SEK 0.6 million in total, including pro rata from CEO Martin Welschof and Chairman Leonard Kruimer
Use of proceeds: Strengthen financial position and fund clinical development of priority programs, principally BI-1808 and BI-1206 in solid tumors
Decks
Investor Presentation (October 2026)
Investor deck · 49 slides · October 2026
Investor Presentation (October 2026)
Investor deck · 46 slides · October 2026
Investor Presentation (September 2026)
Investor deck · 47 slides · September 2026
Investor Presentation (May 2026)
Investor deck · 43 slides · May 27, 2026
BioInvent International AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 30 in all · newest Oct 28, 2026 · oldest 2025
- Calls
- 2 calls with a replay · 2 with a transcript · latest Feb 26, 2026
- Decks
- 15 decks · latest October 2026
Where BioInvent International AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:BINV · Home listing | Stockholm | Sweden | SEK |
| Aquis:BINVS | Aquis | United Kingdom | SEK |
| Stuttgart:BIX0 | Stuttgart | Germany | EUR |
| LS Exchange:A2QJRW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2QJRW | Lang & Schwarz | Germany | EUR |
| gettex:BIX0 | gettex | Germany | EUR |
| Frankfurt:BIX0 · This page | Frankfurt | Germany | EUR |
| Dusseldorf:BIX0 | Dusseldorf | Germany | EUR |
| LSIN:0H22 | LSIN | United Kingdom | SEK |
| Munich:BIX0 | Munich | Germany | EUR |
| OTC:BOVNF | OTC | United States | USD |
| Aquis:BINVS | Aquis | United Kingdom | SEK |
| Turquoise:BINVS | Turquoise | United Kingdom | SEK |
Log in to ask 6ix AI your own questions about BioInvent International AB.